S&P 500
(0.05%) 5 251.00 points
Dow J
(0.01%) 39 764 points
Nasdaq
(-0.08%) 16 386 points
Oil
(1.79%) $82.81
Gas
(0.58%) $1.728
Gold
(1.26%) $2 240.60
Silver
(1.11%) $25.03
Platinum
(1.41%) $922.50
USD/EUR
(0.23%) $0.926
USD/NOK
(0.64%) $10.84
USD/GBP
(-0.04%) $0.791
USD/RUB
(0.12%) $92.55

Realtime updates for Santen Pharmaceutical [SNPHF]

Exchange: OTC Sector: Healthcare Industry: Drug Manufacturersā€”General
Last Updated15 Mar 2024 @ 12:19

-3.02% $ 9.45

Live Chart Being Loaded With Signals

Commentary (15 Mar 2024 @ 12:19):

Warning: Trying to access array offset on null in /home/getagraph/public_html/stock.php on line 302

Santen Pharmaceutical Co., Ltd. researches and develops, manufactures, and markets pharmaceuticals and medical devices in Japan and internationally. It offers various pharmaceutical products to treat glaucoma and ocular hypertension, such as DE-111, which is in Phase III clinical trial; DE-117 in Japan; DE-126 that is in Phase IIb clinical trial; DE-128 in Europe, as well as is in Phase II/III clinical trial in the United States; and DE-130A that is in Phase III clinical trial...

Stats
Today's Volume 201.00
Average Volume 330.00
Market Cap 3.43B
EPS $24.13 ( 2023-11-06 )
Last Dividend $0.121 ( 2023-03-30 )
Next Dividend $0 ( N/A )
P/E 19.28
ATR14 $0 (0.00%)

Santen Pharmaceutical Correlation

10 Most Positive Correlations
10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Santen Pharmaceutical Financials

Annual 2023
Revenue: $279.04B
Gross Profit: $166.09B (59.52 %)
EPS: $-38.58
Q3 2023
Revenue: $77.03B
Gross Profit: $44.88B (58.27 %)
EPS: $20.72
Q2 2023
Revenue: $73.42B
Gross Profit: $43.99B (59.91 %)
EPS: $24.60
Q1 2023
Revenue: $72.39B
Gross Profit: $42.37B (58.52 %)
EPS: $27.93

Financial Reports:

No articles found.

Santen Pharmaceutical Dividends

(Q3/22) (Q4/22) (Q1/23) (Q2/23) (Q3/23) (Q4/23) (Q1/24) (Q2/24) (Q3/24) (Q4/24)
$0.111
(N/A)
$0
(N/A)
$0.121
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)

Santen Pharmaceutical Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 4.85 - Stable (2.91%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information
First Dividend $0.0980 2014-03-27
Last Dividend $0.121 2023-03-30
Next Dividend $0 N/A
Payout Date 0000-00-00
Next Payout Date N/A
# dividends 18 --
Total Paid Out $2.40 --
Avg. Dividend % Per Year 0.00% --
Score 3.08 --
Div. Sustainability Score 10.00
Div.Growth Potential Score 4.85
Div. Directional Score 8.00 --
Next Divdend (Est)
(2024-09-23)
$0 Estimate 3.61 %
Dividend Stability
0.29 Very Poor
Dividend Score
3.08
Pay Frequency
Annually
Yearly Payout
Year Amount Yield

Warning: Undefined variable $stockPricesArray in /home/getagraph/public_html/stock.php on line 1111

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for OTC

Symbol Title Last dividend Frequency Years Dividend Yearly Dividend Score
TLPFY Ex Dividend Junior 2023-04-19 Annually 0 0.00%
KGSPY Ex Dividend Knight 2023-09-07 Semi-Annually 0 0.00%
CKHGY Ex Dividend Junior 2023-05-11 Annually 0 0.00%
RGPCF Ex Dividend Junior 2023-09-01 Semi-Annually 0 0.00%
FSNUY Ex Dividend Junior 2023-05-18 Annually 0 0.00%
AMEN Ex Dividend Knight 2023-10-05 Quarterly 0 0.00%
UNBK No Dividend Player 2023-05-05 Insufficient data to determine frequency 0 0.00%
MCBK Ex Dividend Junior 2023-05-02 Annually 0 0.00%
COIHY Ex Dividend Knight 2023-08-31 Semi-Annually 0 0.00%
SFRGY Ex Dividend Junior 2023-05-22 Annually 0 0.00%

Dividend Sustainability Score (DSS)

RatioActual ValueWeightNormalized ValueScoreRange
netProfitMarginTTM0.09181.5008.1610.00[0 - 0.5]
returnOnAssetsTTM0.06481.2007.849.41[0 - 0.3]
returnOnEquityTTM0.09241.500-0.0848-0.127[0.1 - 1]
payoutRatioTTM0.429-1.0005.71-5.71[0 - 1]
currentRatioTTM2.460.8002.722.17[1 - 3]
quickRatioTTM1.8410.8003.883.10[0.8 - 2.5]
cashRatioTTM0.8971.5006.139.19[0.2 - 2]
debtRatioTTM0.0786-1.5008.69-10.00[0 - 0.6]
interestCoverageTTM20.131.0003.663.66[3 - 30]
operatingCashFlowPerShareTTM192.602.0010.0010.00[0 - 30]
freeCashFlowPerShareTTM162.212.0010.0010.00[0 - 20]
debtEquityRatioTTM0.113-1.5009.55-10.00[0 - 2.5]
grossProfitMarginTTM0.6061.0003.243.24[0.2 - 0.8]
operatingProfitMarginTTM0.1431.0009.149.14[0.1 - 0.6]
cashFlowToDebtRatioTTM2.031.00010.0010.00[0.2 - 2]
assetTurnoverTTM0.7060.8008.636.90[0.5 - 2]
Total Score11.14

Dividend Growth Score (DGS)

RatioActual ValueWeightNormalized ValueScoreRange
peRatioTTM18.241.0008.260[1 - 100]
returnOnEquityTTM0.09242.50-0.0545-0.127[0.1 - 1.5]
freeCashFlowPerShareTTM162.212.0010.0010.00[0 - 30]
dividendYielPercentageTTM0.02381.5009.410[0 - 0.4]
operatingCashFlowPerShareTTM192.602.0010.0010.00[0 - 30]
payoutRatioTTM0.4291.5005.71-5.71[0 - 1]
pegRatioTTM-0.0007691.500-3.340[0.5 - 2]
operatingCashFlowSalesRatioTTM0.2251.0006.860[0.1 - 0.5]
Total Score4.85

Santen Pharmaceutical

Santen Pharmaceutical Co., Ltd. researches and develops, manufactures, and markets pharmaceuticals and medical devices in Japan and internationally. It offers various pharmaceutical products to treat glaucoma and ocular hypertension, such as DE-111, which is in Phase III clinical trial; DE-117 in Japan; DE-126 that is in Phase IIb clinical trial; DE-128 in Europe, as well as is in Phase II/III clinical trial in the United States; and DE-130A that is in Phase III clinical trial. In addition, the company provides DE-114A to treat allergic conjunctivitis; DE-076C for the treatment of vernal keratoconjunctivitis; and DE-109, which is in Phase III clinical trial to treat uveitis. Further, it offers DE-127 to treat myopia, which is in Phase II/III clinical trial in Japan, as well as is in Phase III in Asia; DE-089C, which has completed Phase III clinical trials for the treatment of dry eye; and STN1013400, which is in Phase I clinical trials for the treatment of myopia. Additionally, the company offers over-the-counter pharmaceutical products. The company was formerly known as Santendo Pharmaceutical Co., Ltd. and changed its name to Santen Pharmaceutical Co., Ltd. in 1958. Santen Pharmaceutical Co., Ltd. was founded in 1890 and is headquartered in Osaka, Japan.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators